ArticleMedicine2017
Autoimmune diseases and HIV infection: A cross-sectional study.
Article in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Immune reconstitution inflammatory syndrome, a controversial burden in the East African context: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Antinuclear antibody (ANA) screening based on EULAR/ACR 2019 clinical domain criteria among PLHIV and profile of diagnosed HIV-SLE cases.AIDS research and therapy · 2026Article
- Prevalence of Autoimmune Diseases in Individuals Living with HIV in Korea: A Nationwide Population-Based Study.Medicina (Kaunas, Lithuania) · 2026Article
- Ischemic cerebrovascular accident in an HIV patient: Neurosyphilis and antiphospholipid syndromeBiomedica : revista del Instituto Nacional de Salud · 2026Article
- Elevated Serum Lipopolysaccharides and Intrinsic Factor Autoantibodies Correlate With Macrocytic Anemia Among People With HIV.Immunity, inflammation and disease · 2026Article
- Anti-GPIIIa antibody and CD4 count identify an autoimmune-enriched phenotype of HIV-associated thrombocytopenia: development and internal validation of a clinical nomogram.Frontiers in immunology · 2026Article
- Estrogen Modulation of B Cell Immunity: Implications for HIV Control and Therapeutic Strategies.Comprehensive physiology · 2025Review
- Mapping of the Antinuclear Autoantibodies in Sudanese patients infected with Human Immunodeficiency Virus after HAART receiving: A cross-sectional study.Scientific reports · 2025Article
- Innovative Use of Fostamatinib in Managing Refractory Immune Thrombocytopenia in an HIV-Positive Patient: A Case Report.Clinical case reports · 2025Article
- Therapeutic efficacy ofJournal of traditional and complementary medicine · 2025Article
- Characteristics and outcomes of biopsy-proven lupus nephritis in the Eastern Cape province of South Africa.Lupus · 2024Article
- Persistently Elevated Expression of Systemic, Soluble Co-Inhibitory Immune Checkpoint Molecules in People Living with HIV before and One Year after Antiretroviral Therapy.Pathogens (Basel, Switzerland) · 2024Observational
- Anti-neurofascin 155 Antibody-positive Neuropathy in a Human Immunodeficiency Virus-infected Patient.Internal medicine (Tokyo, Japan) · 2024Article
- Unique Profile of Proinflammatory Cytokines in Plasma of Drug-Naïve Individuals with Advanced HIV/TB Co-Infection.Viruses · 2023Article
- [Neuromyelitis optica spectrum disorder in a patient with human immunodeficiency virus].Revista medica del Instituto Mexicano del Seguro Social · 2023Article
- The demographics of autoimmune hepatitis in human immunodeficiency virus-infected patients: a United States cross-sectional study.Przeglad gastroenterologiczny · 2023Article
- Interaction of the viral infectious agents in the development and exacerbation of the multiple sclerosis.Le infezioni in medicina · 2023Review
- Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies.Frontiers in immunology · 2023Article
- Impact and Tolerance of Immunosuppressive Treatments in Patients Living with HIV with Inflammatory or Autoimmune Diseases.Microorganisms · 2022Article
- Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19.The lancet. HIV · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To describe the clinical manifestations, treatments, prognosis, and prevalence of autoimmune diseases (ADs) in human immunodeficiency virus (HIV)-infected patients.All HIV-infected patients managed in the Infectious Diseases Department of the Lyon University Hospitals, France, between January 2003 and December 2013 and presenting an AD were retrospectively included.Thirty-six ADs were found among 5186 HIV-infected patients which represents a prevalence of 0.69% including immune thrombocytopenic purpura (n = 15), inflammatory myositis (IM) (n = 4), sarcoidosis (n = 4), Guillain-Barré syndrome (GBS) (n = 4), myasthenia gravis (n = 2), Graves' disease (n = 2), and 1 case of each following conditions: systemic lupus erythematosus, rheumatoid arthritis, autoimmune hepatitis, Hashimoto thyroiditis and autoimmune hemolytic anemia. One patient presented 2 ADs. Thirty patients were known to be HIV-infected when they developed an AD. The AD preceded HIV infection in 2 patients. GBS and HIV infection were diagnosed simultaneously in 3 cases. At AD diagnosis, CD4 T lymphocytes count were higher than 350/mm in 63% of patients, between 200 and 350/mm in 19% and less than 200/mm in 19%. Twenty patients benefited from immunosuppressant treatments, with a good tolerance.ADs during HIV infection are uncommon in this large French cohort. Immune thrombocytopenic purpura, sarcoidosis, IM, and GBS appear to be more frequent than in the general population. Immunosuppressant treatments seem to be effective and well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.